One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

Editorial: Polling shows that the public supports this new technology, but the conversation must move beyond simple questions of safety ...

Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years ...

The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...

The Gene Editing Therapeutics market, driven by advancements in CRISPR technology and precision medicine, presents opportunities in oncology, rare genetic disorders, and chronic diseases. Investment ...

Researchers discovered the secret checkpoints that keep CRISPR precise, revealing how the tool shifts from inactive to active without misfiring. The insight could transform gene therapy, making ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these ...

People living with hereditary angioedema, a rare genetic condition that triggers sudden, painful swelling of the face, throat ...